Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
$44.15
$44.17
$16.02
$45.23
$913.91M1.03704,539 shs1.24 million shs
Evolus, Inc. stock logo
EOLS
Evolus
$9.27
+0.7%
$10.02
$8.67
$17.82
$593.82M0.97754,518 shs424,231 shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$0.91
-0.6%
$0.71
$0.28
$2.45
$331.09M1.136.84 million shs1.65 million shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.70
-1.7%
$1.68
$1.15
$3.50
$12.10M-0.3422,859 shs3,539 shs
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$1.03
$1.01
$0.32
$1.57
$211.41M2.151.93 million shsN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
0.00%0.00%0.00%0.00%0.00%
Evolus, Inc. stock logo
EOLS
Evolus
+0.65%-0.43%-6.93%-13.28%-15.65%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-0.64%-2.08%+43.99%+117.24%-45.18%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-0.29%-6.03%-3.13%+24.09%-45.86%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
3.6052 of 5 stars
3.50.00.03.50.63.30.6
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.5345 of 5 stars
3.23.00.00.01.42.50.6
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
3.19 of 5 stars
3.04.00.04.60.00.01.3
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.5433 of 5 stars
0.00.00.04.70.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
0.00
N/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$23.75156.20% Upside
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.40
Hold$3.67302.93% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$5.00194.12% Upside
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SPPI, LXRX, NERV, ALBO, and EOLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
5/8/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
4/17/2025
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/10/2025
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
4/9/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
$40.58M22.52N/AN/A$9.11 per share4.85
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M2.24N/AN/A$0.09 per share103.00
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$31.08M10.58N/AN/A$0.40 per share2.28
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/A$0.21 per share8.28($3.67) per shareN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$10.11M20.91N/AN/A$0.15 per share6.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/A
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$200.40M-$0.51N/AN/AN/A-568.04%-103.16%-54.95%7/30/2025 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.44M$0.822.07N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/A

Latest SPPI, LXRX, NERV, ALBO, and EOLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Evolus, Inc. stock logo
EOLS
Evolus
-$0.09N/AN/AN/A$82.18 millionN/A
5/13/2025Q1 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million
5/13/2025Q1 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$1.07-$0.50+$0.57-$0.50N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
N/A
6.32
6.23
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.34
2.16
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.48
2.22
2.22
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
9.21
9.21
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/A
2.71
2.38

Institutional Ownership

CompanyInstitutional Ownership
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
94.25%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
21.67%
CompanyEmployeesShares OutstandingFree FloatOptionable
Albireo Pharma, Inc. stock logo
ALBO
Albireo Pharma
13020.70 million19.27 millionOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.48 million60.67 millionOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140361.49 million311.25 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
96.99 million6.39 millionNot Optionable
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
86205.25 million199.70 millionOptionable

Recent News About These Companies

Spectrum Thin Films, Inc.
Company History - Paam Drugs and Pharmaceuticals

New MarketBeat Followers Over Time

Media Sentiment Over Time

Albireo Pharma stock logo

Albireo Pharma NASDAQ:ALBO

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Evolus stock logo

Evolus NASDAQ:EOLS

$9.27 +0.06 (+0.65%)
As of 07/3/2025 02:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$0.91 -0.01 (-0.64%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$0.91 0.00 (0.00%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$1.70 -0.03 (-1.73%)
As of 07/3/2025 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Spectrum Pharmaceuticals stock logo

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.